Wacker Chemie

A precipitous step deeper into the CDMO business

23/11/20 -"Wacker's Biosolutions business has become a partner of choice for German mRNA player CureVac. Currently, the technology transfer for the production of CureVac's COVID-19 vaccine candidate is being ..."

PDF page sample
Pages
55
Language
English
Published on
23/11/20
Download
You may also be interested by these reports :
03/08/26
Umicore posted strong results for H1 2026, driven by market share gains in Catalysis and a metals rally in Q1. However, we see a repeat of H1 in the ...
31/07/26
Fuchs reported strong Q2 numbers, supported by positive pricing and market share gains – likely temporary. Growth in sales and earnings was recorded ...
31/07/26
Clariant reported strong Q2 results, with outperformance across segments against street estimates. The performance was led primarily by pricing on a ...
31/07/26
The group reported expected results for Q226, with no significant surprises in operational performance or outlook. Management reiterated confidence ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO